此為 AI 翻譯內容，經編輯審核後發布。
世衛：剛果伊波拉應變取得進展，但疫情「遠未結束」
作者：Siddhi MahatoleBy Siddhi Mahatole
9 月 16 日（路透社）——世界衛生組織週三表示，剛果民主共和國遏制伊波拉疫情的措施已出現令人鼓舞的進展跡象，但也警告，這波疫情「遠未結束」。Sept 16 (Reuters) - The World Health Organization said on Wednesday there were encouraging signs measures to contain an Ebola epidemic in Democratic Republic of Congo were gaining ground, though it warned the outbreak was "far from over."
世衛秘書長譚德塞表示，在伊圖里省受影響最嚴重的地區，傳播情況正在下降。Transmission was declining in the most affected parts of Ituri province, WHO Director-General Tedros Adhanom Ghebreyesus said.
他在一場電話會議中說：「我們現在開始看到令人鼓舞的跡象，顯示我們正在取得進展。」但他也警告，在人口流動性非常高的地區，疫情仍可能擴散。"We are now starting to see encouraging signs that we are gaining ground," he said in a conference call but warned the outbreak could still spread in a region with very high population mobility.
截至 9 月 11 日，剛果已通報逾 7,000 例伊波拉確診病例。Congo had reported more than 7,000 confirmed Ebola cases as of September 11.
這波疫情已擴散至第七個省，是有紀錄以來致死性第二高的伊波拉疫情，僅次於 2014 年至 2016 年在西非延續的那場疫情。The outbreak, the second most lethal on record behind one in West Africa that lasted from 2014 to 2016, has spread to a seventh province.
世衛疫情與大流行威脅管理代理主任瑪麗亞・范科霍芙表示，監測改善可能使檢出的病例數增加，接觸者追蹤工作也已加強。Improved surveillance could lead to an increase in detected cases, while contact-tracing efforts had also increased, said Maria Van Kerkhove, WHO's acting director of epidemic and pandemic threat management.
范科霍芙說：「我們前方還有很多、很多個月要走。這遠未結束。」"We have many, many months ahead of us," Van Kerkhove said. "This is far from over."
世衛健康科學、研究、證據與品質主任梅格・多赫蒂表示，已有超過 3,000 名醫療與第一線工作人員接種默克的 Ervebo 疫苗。More than 3,000 healthcare and frontline workers had already been vaccinated with Merck's Ervebo, said Meg Doherty, WHO's director of science, research, evidence and quality for health.
Ervebo 獲准用於對抗薩伊伊波拉病毒，但其對造成當前疫情的本迪布焦病毒是否有效，目前尚不清楚。Ervebo is licensed against Zaire ebolavirus, but its effectiveness against the Bundibugyo virus driving the current outbreak is not known.
多赫蒂表示，一項針對第一線工作人員的觀察性研究預計很快展開，以評估這款疫苗的有效性；另一項由剛果國家生物醫學研究所與其他合作夥伴主導、處於中後期階段的試驗，預計將在未來幾週啟動。Doherty said an observational study involving frontline workers was expected to begin shortly to assess the vaccine's effectiveness, while a separate mid-to-late-stage trial, led by Congo's National Institute of Biomedical Research with other partners, was expected to get under way in the coming weeks.
她表示，Ervebo 將是該試驗中首批接受效力評估的疫苗之一，之後將評估其他專門針對本迪布焦伊波拉的候選疫苗，包括莫德納的候選疫苗，以及牛津大學的一款候選疫苗。Ervebo will be among the first vaccines evaluated for efficacy in the trial, followed by other vaccine candidates specifically targeting Bundibugyo Ebola, she said. These include candidates from Moderna and one from the University of Oxford.
（Siddhi Mahatole 班加羅爾報導；Pooja Desai 編輯）(Reporting by Siddhi Mahatole in Bengaluru; Editing by Pooja Desai)